Summary.-The effect of the nitroimidazoles misonidazole, Ro-05-9963, and metronidazole on nerve conduction velocity (NCV) were measured in the anaesthetized mouse. The compounds were administered by i.p. injection either as a single dose of 1 mg/g (only 0O5 mg/g for RGW-608) or in 36 fractions of 0O15 mg/g over 18 days (only 4 fractions in 2 days for RGW-608). After single doses a reduction in nerve conduction velocity was seen with all the compounds except metronidazole, which had no significant effect. During chronic exposure, a reduction in NCV occurred towards the end of the course of injections. All compounds produced an effect, although RGW-608 was the most neurotoxic, giving the largest reduction in NCV after only 4 injections. After the end of chronic exposure to misonidazole, Ro-05-9963 and metronidazole, recovery to normal took 2-3 weeks.
As DRUGS which sensitize hypoxic cells to radiation become more widely used in the treatment of cancer it is increasingly important to maximize the benefit they may give to the patient. The relationship between sensitizer enhancement ratio and drug concentration has been established for many compounds both in vitro (Adams et al., 1971; Chapman et al., 1972; Asquith et al., 1974) and in viro (Denekamp et at., 1974; Rauth & Kaufman, 1975; McNally et al., 1978) and it is clear that greater sensitization of hypoxic cells is achieved by higher concentrations of drug. However, it was evident from the first clinical trials (Urtasun et al., 1977; Dische et al., 1977; Kogelnik et al., 1978) using misonidazole, the most promising radiosensitizer to be developed so far, that the dose of drug which can be tolerated would be limited by its neurotoxicity. In all cases the peripheral sensory nerves were affected, first inducing symptoms of paraesthesia in the feet and hands. Only at higher doses were effects on the central nervous system (convulsions) seen (Dische et al., 1977) . Misonidazole is not the only potential radiosensitizer to cause neurological disturbances. Most nitroaromatic compounds when given in high doses, either as radiosensitizers or as chemotherapeutic agents, have produced peripheral neuropathy in man. These include metronidazole and some nitrofurans (LeQuesne, 1975; Coxon & Pallis, 1976) .
In man, minor sensory neurological effects are reported verbally by the patient, but no satisfactory neurological end-point has been developed so far using a small laboratory animal. The present experiments were extensions of the attempt to develop a technique for measuring conduction velocity in peripheral nerves of the mouse (Hirst et al., 1978) with sufficient accuracy for the effects of clinically relevant doses of radiosensitizers to be measured.
The importance of reduction potential in determining the sensitizing efficiency and aerobic cytotoxicity of many nitroaromatic compounds has been demonstrated by Adams et al. (1976a, b) in vitro, but other chemnical properties may also be involved in determining their effect in vivo. In particular, the lipid solubility may influence uptake and excretion, and may also be relevant to the action of the compounds in tissue with a high fat content, such as myelinated nerves. Consequently, 4 drugs with differing octanol/water partition coefficients were selected for the present study (Table) . For structural formulae see Adams et al. (1978a) . The reduction potentials of the 3 2-nitroimidazoles are very similar; metronidazole, a 5-nitroimidazole, has a higher reduction potential, i.e. it is less electron-affinic.
MIATERIALS AND MIETHODS
Motor-nerve conduction velocity Mwas measured in the sciatic nerve of mice using a modification of the technique first described by Helmholz in 1850 and used recently to measure nerve conduction in the rat (Snyder et al., 1977) . A muscle w-as used as the transducer to measure the time taken for an impulse to travel from the point of stimulationi along a motor nerve.
Female CBA mice 12-15 A-eeks old -were anaesthetized -with penthrane and their sciatic nerve and soleus muscle were exposed surgically. The nerve wNas stimulated through glass micropipettes at 2 points separated by an accurately measured distance (typically about 10 mm) and the electrical activity in the muscle produced by each impulse w-as recorded. The delav between each stimulus and its corresponding muscle action potential represented the time taken for conduction from the point of stimulation to the neuromuscular junction, for chemical neuromnuscular transmission. and for propagation of the muscle action potential to the recording probe placed on the muscle surface. By subtracting the total coniduction times -when stimulating at the twro different points, the time taken for the impulse to travel the distance between two stimulating electrodes was obtained. A typical oscilloscope recording of the two events is sho-wn in Fig. 1 .
The details of the technique used in the present study differ from those described previously (Hirst et al., 1978) experiments. In the case of metronidazole the solution had to be warmed to about 40°C shortly before injection to ensure that the compound was completely dissolved.
RESULTS
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The effect of single injections of 4 nitroimidazoles on nerve conduction velocity (NCV) is shown in Fig. 3 )h of the The mean NCV in control animals of )ulse i'S a 39.6J 1 7 mi/s was significantly higher than id as the the velocity reported in a previous experit be con-ment (Hirst et al., 1978) and this is attriseries of buted to sex and age differences in the ion had to mice used (12-15-week-old females in the ted nerve present study and 5-6-week-old males in group of the previous experiment). The magnitude tempera-and time course of the reduction in NCV placed in after misonidazole did not differ signi- Table) than would be predicted from its in vitro cytotoxicity (Adams et at., 1978b ). Animals tested 12 h after only 4 injections, showed a severe reduction in NCV (to 69% of saline control). This dramatic effect is not surprising in view of the relatively high toxicity of the compound which probably causes death through damage to the nervous system. The 3 other compounds produced no reduction in NCV relative to controls 12 h after the 18th injection, but by 12 h after the 36th injection misonidazole and metronidazole had reduced NCV significantly to 83% and 85% of control. The reduction in NCV after Ro-05-9963 at this time was not significant. By 3-5 days after the last injection a significant reduction in NCV was recorded in all drug-treated groups. The biggest effect was a reduction to 75% after metronidazole. By 7*5 and 14-5 days after the last injection, all groups had values within the control range, except those animals tested after misonidazole which showed an "overshoot" to supranormal values.
DISCUSSION
In the development of new radiosensitizers, neurotoxicity appears to be one of the most important limiting factors. At present, very little is known about the chemical properties which determine the degree of neurotoxicity shown in vivo by a given compound.
It is well known that the aerobic cytotoxicity of nitroaromatic compounds is strongly dependent on reduction potential (Adams et al., 1976b; 1978b) . Fig. 5(a, b) shows the maximum reduction in NCV (as a % of the control value) after a single injection of misonidazole, metronidazole, Ro-05-9963 and RGW-608, plotted as a function of aerobic toxicity, and octanol/ water partition coefficient (Adams et al., 1978a, b) . There is a clear indication that those compounds with the greatest in vitro cytotoxicity also show the most neurotoxicity. However, when the 4 compounds were administered at a dose level designed, as far as possible, to reproduce the exposure achieved in patients with misonidazole (Dische et al., 1977) as opposed to the unrealistically large single doses used in the first experiment already described, the dependence of NCV was markedly different (Fig. 5c, d ). There was no clear correlation with aerobic cytotoxicity in vitro, but the octanol/water partition coefficient was more important in determining neurotoxicity. Those compounds showing a relatively higher lipid solubility were more neurotoxic. From this result it is reasonable to speculate that the tissues at risk from the actions of these compounds are those containing a high concentration of lipid. The myelin sheath of peripheral nerves is an obvious target, and this is supported by electron-microscopic evidence of damage to the myelin of mouse sciatic nerve (Dawson & Monoghan, 1978) and human peripheral nerve (Urtasun et al., 1978) after misonidazole.
While neurotoxicity is clearly a very important side effect of these radiosensitizers, it is probably not the only one. This is supported by the observation that the acute LD50 values (Table) correlate only very roughly with the reduction in NCV after single doses.
CONCLUSIONS
In these experiments we have been able to measure nerve conduction velocity in the mouse with an accuracy which detected changes of the order of 10%. The method would seem to offer better resolution than other physiological tests, and has enabled the effects of "clinically relevant" doses of radiosensitizers to be detected and quantified. However, there are a number of disadvantages which ought to be considered before embarking on any major drug-testing programme. It is an invasive method requiring a large number of experimental animals which do not survive the tests; it is also restricted to measurements of motor nerves, while all the available clinical evidence suggests that these neuropathies are principally sensory. The need for large temperature corrections is clearly a weakness of the technique, particularly in view of the large effect of the temperature on NCV, and in the development of any future system accurate temperature control should have a high priority. Finally, the relative effects of the tested compounds are not wholly consistent with clinical experience to date. The relatively large changes produced by metronidazole in the multiple-dose experiment were particularly surprising, as it can be administered in considerably higher doses to patients (by a factor of 3-5) than misonidazole before encountering neurological complications (Urtasun et al., 1975; Dische et al., 1977; Urtasun et al., 1977; Karim, 1978; Kogelnik et al., 1978) . In addition, the wide discrepancy between the toxicity of metronidazole given acutely and as multiple fractions cannot be explained.
In an attempt to overcome some of the shortcomings of the present system a noninvasive end-point is being developed, to investigate further the problem of neurotoxicity in existing and potential radiosensitizers. The method depends on measuring the reaction time between a mild sensory stimulus (tactile and auditory) and the change in electrical activity which this elicits in the muscle of the thigh, as detected by recording electrodes placed on the skin. always positive. If the inter-electrode distance is known, the final count is thus an indication of nerve conduction velocity. The counter output is stored and displayed at the end of a 10s delay, initiated at the end of the measurement, or upon a manual command. The electronic subtraction of the 2 stimulus/ response time delays is the only major improvement over the system previously described in Hirst et al. (1978) .
Circuitry which inhibits the generation of the "close gate" pulse during the stimulus period is also provided. This prevents any stimulus artefact, as picked up by the response electrode, from interfering with the operation of the logic. To facilitate the settingup of the threshold control, a proportion of the "close gate" impulse was added to the response waveform as displayed by the oscilloscope. The position of the threshold point along the waveform could thus be easily observed. As far as the stimulus pulse was concerned, both the width and the amplitude of the pulse were variable (2-100 tus and 0-50 uA negative respectively).
The circuitry is built in a modular format, conveniently subdivided into a display module, a control logic and up/down counter module and an analogue input/output module. The logic sections were assembled using the RCA C04000 family of integrated circuits.
APPENDIX II TISSUE EXPOSURE TO DRUG It is not possible to produce in the mouse the precise tissue exposure to misonidazole achieved in man. This is mainly because the half-life in man is at least 6 x that in the mouse . However, in the chronic exposure experiment an attempt was made to match 2 aspects of the drugexposure pattern.
(1) Peak concentration A dose of 0 15 mg/g of misonidazole was found to give a peak plasma level of 70 0+ 2-5 Hug/ml in the strain of mice used for the present experiments. This dose was chosen to give a similar peak plasma level to that measured in patients during a recent clinical trial (Dische et al., 1977) .
(2) Integrated exposure
The interval between drug doses was chosen so that the total area under the plasma concentration/time plot was the same as that for patients receiving 6 fractions in 18 days. 36 fractions in 18 days was considered to be a good approximation, although it obviously had more fluctuations than in the corresponding 6 fractions exposure in patients. This injection schedule w%as then used for all the compounds tested.
